Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on rare hematology diseases and rare diseases of the immune system, with a core emphasis on CXCR4‑targeted therapies. Its news flow frequently centers on the development and commercialization of mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI® in its first indication and under active investigation in chronic neutropenia and other rare hematologic conditions.
On this page, readers can review news items that X4 has issued about its clinical, corporate and financial milestones. These include updates on the global, pivotal Phase 3 4WARD trial in chronic neutropenia, where mavorixafor is being evaluated as an oral, once‑daily therapy with or without G‑CSF in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who experience recurrent and serious infections. News coverage also highlights Phase 2 trial data demonstrating durable increases in absolute neutrophil count, reductions or discontinuation of injectable G‑CSF in many participants, and safety observations consistent with previous mavorixafor studies.
Investors and observers will also find press releases on financing transactions such as private placements of common stock and pre‑funded warrants, underwritten public offerings, and an equity purchase agreement with Lincoln Park Capital Fund, LLC. These announcements describe how X4 intends to fund the pivotal development of mavorixafor in chronic neutropenia and support its commercialization activities. Additional news items cover organizational restructuring, workforce reductions, leadership and board changes, and participation in healthcare and hematology conferences where X4 presents clinical data and corporate updates.
By following XFOR news, readers can track how X4 Pharmaceuticals reports progress in its rare hematology programs, interprets emerging clinical results for mavorixafor, and manages its capital structure and operations as it advances its CXCR4‑based therapeutic strategy.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. On April 29, 2022, the Compensation Committee granted options to purchase 21,000 shares of common stock at an exercise price of $1.29 per share. The options will vest over four years, starting with 25% after 12 months. X4 focuses on developing novel therapies for immune system disorders, with its lead candidate mavorixafor in Phase 3 trials for WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) announced a poster presentation at the AACR Annual Meeting 2022 in New Orleans, from April 8-12, 2022. The poster, titled Mavorixafor Enhances Efficacy of Bruton’s Tyrosine Kinase Inhibitors, will detail mavorixafor’s role in overcoming bone marrow stroma protections in Waldenström’s macroglobulinemia. Presenter Chi Nguyen, Ph.D., will share insights on April 10, 1:30-5 pm CT. Mavorixafor, a leading small molecule therapy, targets CXCR4 and is critical to treating immune system diseases, including WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) announced presentations at two upcoming virtual healthcare conferences. The company will present a corporate overview at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:45 PM ET. Additionally, a fireside chat will occur at the Canaccord Genuity 2022 Horizons in Oncology Virtual Conference on April 14, 2022, from 10:30 AM to 11:00 AM ET. Both events will be available for live streaming and archived on X4's website for 90 days.
X4 Pharmaceuticals (NASDAQ: XFOR) announced on March 31, 2022, that its Board's Compensation Committee issued inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The inducement awards include options for 92,850 shares of common stock at an exercise price of $1.75, equivalent to the stock's closing price on the grant date. These options vest over four years, contingent on ongoing employment. X4 specializes in CXCR4-targeted therapies aimed at treating immune system disorders, with its lead candidate being mavorixafor, currently in clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its fourth-quarter and annual financial results for 2021, reporting a net loss of $30.2 million for Q4 and $88.7 million for the year. Despite increased losses compared to 2020, the company completed enrollment in its pivotal 4WHIM Phase 3 trial for mavorixafor, targeting WHIM syndrome, with top-line data expected in 4Q22. Ongoing trials for chronic neutropenia and Waldenström’s macroglobulinemia are on track, with additional data anticipated in 2022. As of December 31, 2021, X4 had $83.1 million in cash, projected to fund operations into late 2022.
X4 Pharmaceuticals (Nasdaq: XFOR) will report its Q4 2021 financial results and recent business highlights on March 17, 2022. The company will host a conference call at 8:30 a.m. ET on the same day, accessible via phone or webcast. X4 specializes in developing CXCR4-targeted therapeutics, with its lead candidate, mavorixafor, showing potential in treating immune disorders and certain cancers. Mavorixafor is currently in various clinical trials, including a fully enrolled Phase 3 trial for WHIM syndrome, showcasing the drug's promising efficacy and safety profile.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to engage in high-profile discussions at two upcoming healthcare conferences. The company will participate in the 42nd Annual Cowen Healthcare Conference on March 7, 2022, focusing on a Non-Malignant Hematology Panel at 12:50 PM ET. Additionally, they will host a Fireside Chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 4:00 PM ET. Live webcasts will be available on their website, with recordings accessible for 90 days post-event.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on March 1, 2022, that its Compensation Committee granted inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. This includes options to purchase 22,250 shares and restricted stock units for 3,500 shares. The options have a ten-year term with an exercise price of $1.50 per share, vesting over four years. X4 focuses on developing novel therapies for immune system dysfunction, with its lead candidate mavorixafor currently in global Phase 3 trials and addressing rare diseases like WHIM syndrome.
X4 Pharmaceuticals (XFOR) announced the issuance of inducement awards to new employees as part of its 2019 Inducement Equity Incentive Plan. On January 31, 2022, the Compensation Committee granted options to purchase 33,000 shares and restricted stock units covering 11,000 shares of common stock. The options have a ten-year term with an exercise price of $2.06, vesting over four years. X4 is developing novel therapies for immune dysfunction, with its lead candidate, mavorixafor, undergoing Phase 3 trials for WHIM syndrome.
X4 Pharmaceuticals, a leader in immune system therapeutics, will participate in a fireside chat at the B. Riley Securities Oncology Investor Conference on January 28, 2022, at 1:00 PM ET. The conference will focus on their innovative therapies, including the lead candidate mavorixafor, a novel CXCR4-targeted small molecule. A live webcast will be available on their website, where it will remain archived for 30 days post-event. X4 Pharmaceuticals is dedicated to advancing treatments for various immune system dysfunctions and has ongoing clinical trials for its lead candidate.